191 related articles for article (PubMed ID: 11751393)
1. Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma.
Huhn M; Sasse S; Tur MK; Matthey B; Schinköthe T; Rybak SM; Barth S; Engert A
Cancer Res; 2001 Dec; 61(24):8737-42. PubMed ID: 11751393
[TBL] [Abstract][Full Text] [Related]
2. CD30L-ETA': a new recombinant immunotoxin based on the CD30 ligand for possible use against human lymphoma.
Barth S; Matthey B; Huhn M; Diehl V; Engert A
Cytokines Cell Mol Ther; 1999 Jun; 5(2):69-78. PubMed ID: 10515679
[TBL] [Abstract][Full Text] [Related]
3. An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line.
Klimka A; Barth S; Matthey B; Roovers RC; Lemke H; Hansen H; Arends JW; Diehl V; Hoogenboom HR; Engert A
Br J Cancer; 1999 Jun; 80(8):1214-22. PubMed ID: 10376974
[TBL] [Abstract][Full Text] [Related]
4. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
5. Angiogenin single-chain immunofusions: influence of peptide linkers and spacers between fusion protein domains.
Newton DL; Xue Y; Olson KA; Fett JW; Rybak SM
Biochemistry; 1996 Jan; 35(2):545-53. PubMed ID: 8555226
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies.
Franke AC; Jung D; Ellis TM
Hybridoma; 2000 Feb; 19(1):43-8. PubMed ID: 10768840
[TBL] [Abstract][Full Text] [Related]
7. CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.
Wendtner CM; Schmitt B; Gruss HJ; Druker BJ; Emmerich B; Goodwin RG; Hallek M
Cancer Res; 1995 Sep; 55(18):4157-61. PubMed ID: 7545087
[TBL] [Abstract][Full Text] [Related]
8. Reverse signaling via CD30 ligand.
Wiley SR; Goodwin RG; Smith CA
J Immunol; 1996 Oct; 157(8):3635-9. PubMed ID: 8871664
[TBL] [Abstract][Full Text] [Related]
9. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
[TBL] [Abstract][Full Text] [Related]
10. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
[TBL] [Abstract][Full Text] [Related]
11. [Construction and expression of the fusion protein DT389-hIL-13 and its cytotoxicity to glioma cell lines].
Tuo HZ; Wang JW; Wang DX; Li JM; Ouyang J; Hong T
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(12):1024-8. PubMed ID: 15312540
[TBL] [Abstract][Full Text] [Related]
12. Small cleavable adapters enhance the specific cytotoxicity of a humanized immunotoxin directed against CD64-positive cells.
Hetzel C; Bachran C; Fischer R; Fuchs H; Barth S; Stöcker M
J Immunother; 2008 May; 31(4):370-6. PubMed ID: 18391759
[TBL] [Abstract][Full Text] [Related]
13. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice.
Sun X; Yamada H; Shibata K; Muta H; Tani K; Podack ER; Yoshikai Y
J Immunol; 2010 Aug; 185(4):2222-30. PubMed ID: 20639486
[TBL] [Abstract][Full Text] [Related]
14. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
[TBL] [Abstract][Full Text] [Related]
15. Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning.
Klimka A; Matthey B; Roovers RC; Barth S; Arends JW; Engert A; Hoogenboom HR
Br J Cancer; 2000 Jul; 83(2):252-60. PubMed ID: 10901379
[TBL] [Abstract][Full Text] [Related]
16. CD30: expression and function in health and disease.
Horie R; Watanabe T
Semin Immunol; 1998 Dec; 10(6):457-70. PubMed ID: 9826579
[TBL] [Abstract][Full Text] [Related]
17. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.
Bremer E; Samplonius DF; Peipp M; van Genne L; Kroesen BJ; Fey GH; Gramatzki M; de Leij LF; Helfrich W
Cancer Res; 2005 Apr; 65(8):3380-8. PubMed ID: 15833872
[TBL] [Abstract][Full Text] [Related]
18. [Construction, expression and refolding of recombinant luteinizing hormone releasing hormone-angiogenin toxin].
Ni ZL; Zhang QH; Qu QY; Lü HL; Fan SY; Cai C
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Aug; 45(8):680-4. PubMed ID: 21055247
[TBL] [Abstract][Full Text] [Related]
19. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells.
Gruss HJ; Ulrich D; Braddy S; Armitage RJ; Dower SK
Eur J Immunol; 1995 Jul; 25(7):2083-9. PubMed ID: 7621881
[TBL] [Abstract][Full Text] [Related]
20. CD30 ligand in lymphoma patients with CD30+ tumors.
Younes A; Consoli U; Snell V; Clodi K; Kliche KO; Palmer JL; Gruss HJ; Armitage R; Thomas EK; Cabanillas F; Andreeff M
J Clin Oncol; 1997 Nov; 15(11):3355-62. PubMed ID: 9363866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
